Oncology Chemotherapeutic Drugs

First line treatment of advanced / metastatic breast cancer (hormone receptor positive or receptor status unkown) in postmenopausal women.

Each film coated tablet contains Letrozole USP 2.5mg.

1 x 3 x 10's per box

The recommended dose of Letrozole is 2.5 mg once daily. Treatment with Letrozole should continue as long as tumor response is seen. The drug should be discontinued if tumor stops responding as judged by tumor progression.

Mamazol is contraindicated in known or suspected hypersensitivity to letrozole, other aromatase inhibitors, or to any of their ingredients. It is contraindicated during pregnancy, lactation and in premenopausal women. It is also contraindicated in severe hepatic dysfunction.

Adverse events associated with letrozole are generally mild to moderate and rarely severe enough to require discontinuation. Many can be attributed to either the underlying disease or the normal pharmacological open consequence of ostrogen deprivation (hot flushes, hair thinning). The most frequently reported adverse events are musculoskeletal pain, arthralgia, headache, fatigue, nausea, dyspnoea, peripheral edema, coughing. constipation, vomiting, chest pain, viral infection, diarrhoea rash, abdominal pain, dyspepsia and anorexia, Dizziness, weight increase and pruritus are less commonly seen.

Clinical interaction studies with cimetidine and warfarin indicated that the co-administration of letrozole with these drugs does not result in clinically significant drug interactions, even though cimetidine is a known inhibitor of one of the cytochrome P450 isoenzymes capable of metabolizing letrozole in vitro.

KHANDELWAL Laboratories.,India